Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Erba

Showing results (51-60 of 162) with videos related to

Pageof 17
Sort By:
Leukemia & Lymphoma|February 9, 2021
Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203Anna Moseley, Megan Othus, Guillermo Garcia-Manero, et al.
Expert Opinion on Therapeutic Targets|January 12, 2011
Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancerMeng Wang, Bruno C Medeiros, Harry P Erba, et al.
Leukemia|October 14, 2018
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studiesMegan Othus, Mikkael A Sekeres, Sucha Nand, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 9, 2005
'Low dose' 99mTc-Sestamibi for radioguided surgery of primary hyperparathyroidismD Rubello, A Piotto, F Medi, et al.
Sexual Development : Genetics, Molecular Biology, Evolution, Endocrinology, Embryology, and Pathology of Sex Determination and Differentiation|September 16, 2009
Body composition and metabolic profile in women with complete androgen insensitivity syndromeE Dati, G I Baroncelli, S Mora, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 13, 2019
Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOMLauren E Merz, Anthony J Perissinotti, Bernard L Marini, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 17, 2005
(18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patientsC Nanni, D Rubello, M Farsad, et al.
Haematologica|July 14, 2022
Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial dataMegan Othus, Guillermo Garcia-Manero, John E Godwin, et al.
Blood Cancer Journal|May 3, 2025
Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024Daniel J Olivieri, Alexis Berridge-Green, Megan Othus, et al.
Blood Neoplasia|August 12, 2025
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapySuravi Raychaudhuri, Megan Othus, Mary-Elizabeth M Percival, et al.
Pageof 17

Showing results (51-60 of 162) with videos related to

Sort By:
Pageof 17
Leukemia & Lymphoma|February 9, 2021
Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203Anna Moseley, Megan Othus, Guillermo Garcia-Manero, et al.
Expert Opinion on Therapeutic Targets|January 12, 2011
Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancerMeng Wang, Bruno C Medeiros, Harry P Erba, et al.
Leukemia|October 14, 2018
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studiesMegan Othus, Mikkael A Sekeres, Sucha Nand, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 9, 2005
'Low dose' 99mTc-Sestamibi for radioguided surgery of primary hyperparathyroidismD Rubello, A Piotto, F Medi, et al.
Sexual Development : Genetics, Molecular Biology, Evolution, Endocrinology, Embryology, and Pathology of Sex Determination and Differentiation|September 16, 2009
Body composition and metabolic profile in women with complete androgen insensitivity syndromeE Dati, G I Baroncelli, S Mora, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 13, 2019
Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOMLauren E Merz, Anthony J Perissinotti, Bernard L Marini, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 17, 2005
(18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patientsC Nanni, D Rubello, M Farsad, et al.
Haematologica|July 14, 2022
Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial dataMegan Othus, Guillermo Garcia-Manero, John E Godwin, et al.
Blood Cancer Journal|May 3, 2025
Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024Daniel J Olivieri, Alexis Berridge-Green, Megan Othus, et al.
Blood Neoplasia|August 12, 2025
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapySuravi Raychaudhuri, Megan Othus, Mary-Elizabeth M Percival, et al.
Pageof 17